DBV Technologies

Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children

Press Release Montrouge, France, March 5, 2017

Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children

During a Late Breaking Oral Abstract Session, Dr. Shreffler reported that 83.3% of pediatric patients responded to Viaskin Peanut 250 µg after three years with a favorable safety profile and no SAE's related to treatment

An additional oral abstract, presented by FARRP, used a robust risk analysis model to show the significant benefit associated with increasing an individual's peanut protein threshold with immunotherapy

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that detailed results from OLFUS-VIPES, a long-term extension study to the VIPES Phase IIb trial, were presented at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Atlanta, Georgia, at a Late Breaking Oral Abstract Session. The Company previously reported topline results from the OLFUS-VIPES study in October 2016.
"It is encouraging to see that with continued treatment, the effect of Viaskin Peanut for children was sustained or increased throughout three years, while also maintaining a favorable and easily manageable safety profile," said Dr. Wayne Shreffler, Division of Allergy and Immunology, Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School and Investigator of the OLFUS-VIPES Study. "Peanut allergy is one of the leading life-threatening food allergies among children. Even with conscientious avoidance, accidental ingestions are common and can be life-threatening."
Viaskin Peanut Highlights

Viaskin Peanut is the company's lead product candidate, based on its proprietary EPIT platform, which aims to deliver biologically active compounds to the immune system through the skin, and is currently being evaluated in a global, pivotal Phase III program in peanut-allergic children four to 11 years of age. The company also expects to initiate a Phase III trial of Viaskin Peanut in children one to three years of age in the first half of 2017.

Late Breaking Abstract #L7
The 36-month data from the OLFUS-VIPES study, presented by Dr. Wayne Shreffler, support the lasting response and favorable safety and tolerability profile of Viaskin Peanut 250 µg in peanut-allergic children six to 11 years of age. The study was also selected to be highlighted at the "Research in Food Allergy Immunotherapy Press Event" hosted by AAAAI.